Physician profile
Kanitha Sar
NPI 1417402108
$5,740.68
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,023 · 2022: $671 · 2023: $22.01 · 2024: $24.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $46.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $46.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,899.52 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $271.92 | 2021 | |
| Amgen INC. | $192.39 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $171.57 | 2022-2024 | |
| Biogen, INC. | $167.84 | 2021 | |
| Acadia Pharmaceuticals INC | $162.21 | 2021 | |
| Ucb, INC. | $139.79 | 2021 | |
| Eisai INC. | $131.84 | 2021 | |
| Lilly USA, LLC | $129.90 | 2021 | |
| Avanir Pharmaceuticals, INC. | $129.41 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $113.88 | 2021-2022 | |
| Allergan, INC. | $113.53 | 2021 | |
| Alexion Pharmaceuticals, INC. | $111.36 | 2021 | |
| Adamas Pharmaceuticals, INC. | $103.43 | 2021 | |
| Lundbeck LLC | $103.00 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $86.30 | 2021 | |
| Upsher-Smith Laboratories LLC | $73.73 | 2021 | |
| Kyowa Kirin, INC. | $73.10 | 2021 | |
| Novartis Pharmaceuticals Corporation | $72.62 | 2021 | |
| Sunovion Pharmaceuticals INC. | $68.23 | 2021 | |
| Janssen Pharmaceuticals, INC | $59.48 | 2021 | |
| Supernus Pharmaceuticals, INC. | $57.70 | 2021 | |
| Currax Pharmaceuticals LLC | $56.42 | 2021 | |
| Amneal Pharmaceuticals LLC | $49.47 | 2021 | |
| Jazz Pharmaceuticals INC. | $34.85 | 2021 | |
| Genzyme Corporation | $33.04 | 2021 | |
| Csl Behring | $27.41 | 2021 | |
| Paratek Pharmaceuticals, INC. | $22.01 | 2023 | Nuzyra |
| Acorda Therapeutics, INC | $20.66 | 2021 | |
| Pfizer INC. | $19.28 | 2021 | |
| Arbor Pharmaceuticals, INC. | $16.43 | 2021 | |
| Harmony Biosciences LLC | $15.87 | 2021 | |
| Merz Pharmaceuticals, LLC | $12.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kanitha Sar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.